rs41276738 — VWF p.Arg854Gln (R854Q) type 2N

VWF Arg854Gln — When Your Clotting Scaffold Cannot Hold Factor VIII

Von Willebrand factor (VWF) does two things in hemostasis: it plugs gaps in damaged vessel walls by tethering platelets to collagen, and it acts as a carrier protein for coagulation Factor VIII¹¹ coagulation Factor VIII
Factor VIII is the key cofactor in the intrinsic coagulation cascade (tenase complex). Without it, secondary hemostasis — clot reinforcement — fails, producing the hemophilia A phenotype. VWF normally stabilises circulating FVIII and delivers it to the site of vascular injury. The rs41276738 variant disrupts this second role: the scaffold is structurally normal, but it cannot hold its cargo.

The Mechanism

The D' domain of VWF — encoded by exon 18 — is the high-affinity binding site for Factor VIII. Arginine at position 854 is a critical contact residue in this binding pocket. The Arg854Gln substitution (R854Q) replaces this positively charged arginine with a neutral glutamine, disrupting the electrostatic interface between VWF and FVIII without altering VWF secretion, multimer structure, or platelet-tethering activity.

The consequence is type 2N (Normandy) von Willebrand disease²² type 2N (Normandy) von Willebrand disease
Named after the French region where the original kindreds were identified; also called VWD type 2 Normandy. Characterized by markedly reduced VWF affinity for FVIII with normal platelet-dependent hemostasis. FVIII is under-stabilised in circulation and cleared more rapidly, producing reduced plasma FVIII levels — often in the range of 5–30 IU/dL in homozygotes — that precisely mimic mild-to-moderate hemophilia A. VWF antigen and ristocetin cofactor activity are normal or only mildly reduced.

The inheritance pattern is codominant with dose dependency: heterozygous CT carriers have a partial FVIII-binding defect (reduced VWF:FVIIIB/VWF:Ag ratio) that is detectable with laboratory testing but rarely causes spontaneous bleeding. Homozygous TT or compound heterozygous states produce the full clinical phenotype.

The Evidence

Van den Biggelaar et al. (2009)³³ Van den Biggelaar et al. (2009) demonstrated that Arg854Gln causes a moderate FVIII-binding defect in cell studies: unlike severe type 2N mutations (Thr791Met, Arg816Trp), Arg854Gln VWF still traffics to Weibel-Palade bodies and co-recruits FVIII into storage organelles, but FVIII release and stabilisation are compromised. This helps explain why homozygous R854Q patients have less severe FVIII deficiency than those carrying null-allele combinations.

Casonato et al. (2018)⁴⁴ Casonato et al. (2018) conducted a 15-year analysis of 2,178 VWF:FVIIIB assays and found the p.R854Q heterozygous carrier frequency at ~5.2% in northeast Italy — far above the rate one would expect from rare disease status. The VWF:FVIIIB/VWF:Ag ratio was consistently abnormal in carriers, making it the most reliable screening tool.

Daniel et al. (2024)⁵⁵ Daniel et al. (2024), in the largest type 2N cohort to date (123 French patients), stratified outcomes by R854Q genotype. Homozygous R854Q patients (n=55) had significantly higher residual FVIII than compound heterozygotes with null alleles (p<0.0001), and experienced heterogeneous desmopressin responses — with baseline FVIII level predicting desmopressin efficacy. The study confirms genotype-driven phenotype stratification and underscores the need for individualised DDAVP trials.

Practical Actions

The key clinical challenge is that type 2N VWD is routinely misdiagnosed as mild hemophilia A because the laboratory phenotype (low FVIII, normal aPTT when borderline) is identical. The distinguishing test is the VWF:FVIII binding assay (VWF:FVIIIB) — specifically the VWF:FVIIIB/VWF:Ag ratio, which is abnormal even in heterozygous carriers. Molecular confirmation by sequencing VWF exon 20 (where codon 854 resides) should follow any abnormal binding assay.

For homozygous TT carriers, the treatment algorithm differs critically from hemophilia A: desmopressin (DDAVP) acts on endothelial Weibel-Palade body release to transiently raise VWF and co-released FVIII; it can be effective in type 2N but response is variable and must be individually assessed. VWF concentrate (not FVIII concentrate alone) is the treatment of choice when desmopressin is inadequate, because it provides exogenous VWF capable of stabilising endogenous or infused FVIII at the injury site.

Interactions

The ABO blood group locus (rs505922 and related variants) is the strongest known modifier of circulating VWF levels: blood group O individuals have ~25% lower VWF antigen than non-O. In type 2N heterozygotes, who already have a partial FVIII-binding defect, co-inheritance of blood group O may further reduce functional VWF:FVIIIB, compounding the bleeding risk. Full haemostatic phenotype assessment should include ABO blood typing.

Compound heterozygosity — one R854Q allele combined with a null VWF allele (type 1/3 mutations, frame-shifts, or splice variants) — produces a more severe phenotype than R854Q homozygosity, because the null allele contributes no functional VWF while the R854Q allele secretes VWF unable to bind FVIII. Hilbert et al. (2006)⁶⁶ Hilbert et al. (2006) documented such compound heterozygosity with undetectable VWF:FVIIIB and an abnormal multimer profile.